Baxter International ended 2024 on a positive note, overcoming challenges posed by Hurricane Helene and delivering better-than-expected Q4 results. The success of the Novum IQ infusion pump ...

Following the completion of a massive restructuring plan, the medical equipment giant projects 4% to 5% sales growth this year.

周一，UBS分析师Danielle Antalffy更新了Baxter International（NYSE:BAX）的财务展望，将公司目标价从此前的32.50美元上调至35.00美元。尽管作出这一调整，但该机构维持对这家医疗保健公司股票的"中性"评级。目前，该公司股价为35.08美元，市值为179亿美元。根据 InvestingPro ...

Baxter International Inc (BAX) reports robust earnings growth and outlines strategic priorities for 2025 despite facing operational challenges.

So I'll say, we're very happy with the launch of Novum IQ and where we are. The teams are doing a great job driving this new platform. If you recall, Baxter placed a pretty big bet to internally ...

Baxter calculates forward-looking non-GAAP financial measures based on forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, forward-looking ...

primarily driven by the demand for the Novum IQ platform. Despite operational challenges due to Hurricane Helene, Baxter anticipates a resumed production of IV solutions by late November.

This positive performance was partly attributed to the successful launch of the Novum IQ infusion pump, which contributed to a 50% growth in the infusion business. Looking ahead, Baxter has ...